Preliminary results from HERKULES-1: a phase 1b/2, open-label, multi-center study of ERAS-007, an oral ERK1/2 inhibitor, in patients with advanced or metastatic solid tumors

被引：0
|
作者：
Wang, J. [1 ]
Johnson, M. [2 ]
Barve, M. [3 ]
Pelster, M. [2 ]
Chen, X. [4 ]
Li, Z. [4 ]
Gordon, J. [4 ]
Reiss, M. [4 ]
Pai, S. [4 ]
Falchook, G. [5 ]
Tolcher, A. [6 ]
机构：
[1] Florida Cancers Specialists Sarah Cannon Res Inst, Drug Dev Unit, Sarasota, FL USA
[2] Sarah Cannon Res Inst, Tennessee Oncol Drug Dev Unit, Nashville, TN USA
[3] Mary Crowley Canc Res, Res Oncol, Dallas, TX USA
[4] Erasca Inc, San Diego, CA USA
[5] Sarah Cannon Res Inst HealthONE, Drug Dev Unit, Denver, CO USA
[6] NEXT Oncol, Oncol, San Antonio, TX USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
224
引用
收藏
页码：S80 / S81
页数：2
相关论文
共 50 条
  • [41] A phase 1b/2, open-label study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive)
    Dayyani, Farshid
    Lee, Arielle Shebay
    Li, Daneng
    Rowe, Julie Haewon
    Beg, Muhammad Shaalan
    Kasturi, Vijay
    Iyer, Renuka V.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [42] Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
    Thein, Kyaw Zin
    Piha-Paul, Sarina A.
    Tsimberidou, Apostolia
    Karp, Daniel D.
    Janku, Filip
    Zarifa, Abdulrazzak
    Shah, Jatin
    Milton, Denai R.
    Bean, Stacie
    McQuinn, Lacey
    Gong, Jing
    Colen, Rivka
    Carter, Brett W.
    Subbiah, Vivek
    Ogbonna, Deby C.
    Pant, Shubham
    Meric-Bernstam, Funda
    Naing, Aung
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1357 - 1365
  • [43] A FIRST-IN-HUMAN, MULTICENTER, PHASE 1/2, OPEN-LABEL STUDY OF XTX101 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Powderly, John
    Norman, Teleen
    Duncan, Meghan
    Huber, Martin
    O'Neil, Jennifer
    Patel, Ekta
    Vandross, Andrae
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A549 - A549
  • [44] A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
    Varga, A.
    Soria, J. C.
    Hollebecque, A.
    LoRusso, P.
    Vaishampayan, U.
    Okrah, K.
    Huang, S. M. A.
    Murray, E.
    Sanabria-Bohorquez, S.
    Tagen, M.
    Dokainish, H.
    Mueller, L.
    Burris, H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S11 - S11
  • [45] A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
    Varga, Andrea
    Soria, Jean-Charles
    Hollebecque, Antoine
    LoRusso, Patricia
    Bendell, Johanna
    Huang, Shih-Min A.
    Wagle, Marie-Claire
    Okrah, Kwame
    Liu, Lichuan
    Murray, Elaine
    Sanabria-Bohorquez, Sandra M.
    Tagen, Michael
    Dokainish, Hatem
    Mueller, Lars
    Burris, Howard
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1229 - 1236
  • [46] Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
    McKean, M.
    Barve, M.
    Hong, D.
    Parikh, A.
    Rosen, E.
    Yang, J.
    Picard, R.
    Yi, J.
    Brail, L.
    Vecchio, D.
    Meniawy, T.
    John, T.
    Wang, J.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S34 - S34
  • [47] Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
    Moschos, Stergios J.
    Sullivan, Ryan J.
    Hwu, Wen-Jen
    Ramanathan, Ramesh K.
    Adjei, Alex A.
    Fong, Peter C.
    Shapira-Frommer, Ronnie
    Tawbi, Hussein A.
    Rubino, Joseph
    Rush, Thomas S., III
    Zhang, Da
    Miselis, Nathan R.
    Samatar, Ahmed A.
    Chun, Patrick
    Rubin, Eric H.
    Schiller, James
    Long, Brian J.
    Dayananth, Priya
    Carr, Donna
    Kirschmeier, Paul
    Bishop, W. Robert
    Deng, Yongqi
    Cooper, Alan
    Shipps, Gerald W.
    Moreno, Blanca Homet
    Robert, Lidia
    Ribas, Antoni
    Flaherty, Keith T.
    JCI INSIGHT, 2018, 3 (04):
  • [48] A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors
    Dudek, Arkadiusz Z.
    O'Shaughnessy, Joyce
    Piha-Paul, Sarina A.
    Uprety, Dipesh
    Kitchens, Benjamin Lee
    Hutson, Thomas E.
    Rank, Brian H.
    Stokes, Michael
    Dudgeon, Crissy
    Surguladze, David
    Lightcap, Eric
    Drees, Jeremy
    Harrison, Ben
    Li, Richard
    LaCayo, Ashley
    Mattson, Paulette
    Bose, Nandita
    Karim, Dhamina
    Gargano, Michele Anne
    Iglesias, Jose Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Safety and preliminary activity of naptumomab estafenatox (NAP) and durvalumab in patients with advanced or metastatic solid tumors: interim results from a phase 1b trial
    Geva, Ravit
    Stemmer, Salomon
    Perets, Ruth
    Maurice-Dror, Corinne
    Ben-Ami, Eitan
    Raphael, Ari
    Kumar, Sanjeev
    Lorber, Ilana
    Kedem, Tal Hetzroni
    Fields, Scott Z.
    Rozencweig, Marcel
    Golan, Talia
    CANCER RESEARCH, 2023, 83 (08)
  • [50] A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors
    Liao, Mingxiang
    Jeziorski, Krzysztof G.
    Tomaszewska-Kiecana, Monika
    Lang, Istvan
    Jasiowka, Marek
    Skarbova, Viera
    Centkowski, Piotr
    Ramlau, Rodryg
    Gornas, Maria
    Lee, John
    Edwards, Sarah
    Habeck, Jenn
    Nash, Eileen
    Grechko, Nikolay
    Xiao, Jim J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (05) : 887 - 897
12345